title: [Results of a multicenter study of Rebif-22 mcg administration in Russia].
abstract: The results of multicenter study of Rebif 22 micrograms in Russia have been reported. 167 multiple sclerosis patients have received Rebif 22 micrograms three times a week for 1 year. This study provides evidence for reduction of the relapse rate in patients with relapsing/remitting and secondary progressive multiple sclerosis. The tendency to the decrease of the severity of relapses, less need for steroid use and the decrease of EDSS score in patients with relapsing/remitting multiple sclerosis have been shown. In general Rebif 22 micrograms was tolerated well.
authors.forename: I A
authors.initials: IA
authors.lastname: Zavalishin
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
authors.forename: N N
authors.initials: NN
authors.lastname: Iakhno
authors.forename: A A
authors.initials: AA
authors.lastname: Skoromets
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
authors.forename: T L
authors.initials: TL
authors.lastname: Demina
authors.lastname: Burlutskiĭ A P
authors.forename: B N
authors.initials: BN
authors.lastname: Beĭn
authors.forename: I I
authors.initials: II
authors.lastname: Sholomov
authors.forename: A V
authors.initials: AV
authors.lastname: Pereserdova
authors.forename: N I
authors.initials: NI
authors.lastname: Stoĭda
authors.forename: M N
authors.initials: MN
authors.lastname: Zakharova
authors.forename: L S
authors.initials: LS
authors.lastname: Adarcheva
authors.forename: A S
authors.initials: AS
authors.lastname: Niiazbekova
authors.forename: L Sh
authors.initials: LSh
authors.lastname: Askarova
authors.forename: V G
authors.initials: VG
authors.lastname: Oleĭnikov
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Rebrova
authors.forename: T E
authors.initials: TE
authors.lastname: Shmidt
authors.forename: M V
authors.initials: MV
authors.lastname: Davydovskaia
authors.forename: N A
authors.initials: NA
authors.lastname: Totolian
authors.forename: I A
authors.initials: IA
authors.lastname: Beskhmel'nitsina
authors.forename: O V
authors.initials: OV
authors.lastname: Bragina
authors.forename: G L
authors.initials: GL
authors.lastname: Ponomareva
authors.forename: O M
authors.initials: OM
authors.lastname: Durseneva
authors.forename: S A
authors.initials: SA
authors.lastname: Voronchikhina
authors.forename: L I
authors.initials: LI
authors.lastname: Volkova
authors.forename: E L
authors.initials: EL
authors.lastname: Turova
authors.forename: A G
authors.initials: AG
authors.lastname: Streknev
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004185:Disability Evaluation; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a